A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
University of Nebraska
National Institutes of Health Clinical Center (CC)
Takeda
M.D. Anderson Cancer Center